Regular cannabis users more likely to experience postoperative complications, study finds

Spring­Works Ther­a­peu­tics won FDA ap­proval for its desmoid tu­mor treat­ment Og­siveo on Mon­day, fol­low­ing a three-month reg­u­la­to­ry hic­cup. Desmoid tu­mors are rare but lo­cal­ly ag­gres­sive

Plus, news about En­ver­ic Bio­sciences and Kazia Ther­a­peu­tics: John­son & John­son’s bis­pe­cif­ic gets a new dos­ing sched­ule: The FDA ap­proved a re­duced dos­ing reg­i­men for